| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/01/2004 | WO2004026026A1 7f4 gene transgenic animal |
| 04/01/2004 | WO2004014928A3 Novel difluorinated gem compounds, preparation methods thereof and applications of same |
| 04/01/2004 | WO2004009123A3 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 04/01/2004 | WO2004007521A3 Bile acid derivatives as agonists of the farnesoid x receptor |
| 04/01/2004 | WO2004005881A3 Methods for identification of compounds modulating insulin resistance |
| 04/01/2004 | WO2004000354A3 Method of treating the syndrome of lipodystrophy |
| 04/01/2004 | WO2003101932A3 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 04/01/2004 | WO2003099819A3 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics |
| 04/01/2004 | WO2003099281A3 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 04/01/2004 | WO2003099256A3 FREE-FLOWING, POWDERY COMPOSITION CONTAINING α-LIPONIC ACID (DERIVATIVES) |
| 04/01/2004 | WO2003097658A3 Compounds and methods for inhibiting selectin-mediated function |
| 04/01/2004 | WO2003097633A8 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 04/01/2004 | WO2003097597A3 Indole derivatives and the use thereof as cb2 receptor ligands |
| 04/01/2004 | WO2003094933A3 Use of lanthanum for the treatment of hypercalcemia and bone metastasis |
| 04/01/2004 | WO2003084943A3 Terphenyl derivatives, preparation thereof, compositions containing same |
| 04/01/2004 | WO2003084566A3 Proteins involved in the regulation of energy homeostasis |
| 04/01/2004 | WO2003082874A3 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments |
| 04/01/2004 | WO2003079998A3 Treatment of diseases involving defective gap junctional communication |
| 04/01/2004 | WO2003075932A8 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| 04/01/2004 | WO2003074078A3 Cg3842 homologous proteins involved in the regulation of energy homeostasis |
| 04/01/2004 | WO2003070886A3 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
| 04/01/2004 | WO2003067221A3 Compositions and methods for restoring immune responsiveness in patients with immunological defects |
| 04/01/2004 | WO2003066597A3 Guanidino compounds |
| 04/01/2004 | WO2003059874A3 Aromatic thioether liver x-receptor modulators |
| 04/01/2004 | WO2003057205A3 Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs |
| 04/01/2004 | WO2003056029A3 Highly sensitive and continuous protein-tyrosine-phosphatase (ptpase) test using 6,8 difluoro-4-methyl-umbelliferylphosphate |
| 04/01/2004 | WO2003049675A3 Treating muscle wasting with selective androgen receptor modulators |
| 04/01/2004 | WO2003048336A3 Cultured cells from pancreatic islets |
| 04/01/2004 | WO2003026635A3 Improved method of treating the syndrome of type 2 diabetes in humans |
| 04/01/2004 | WO2003008410A8 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 04/01/2004 | WO2002102314A3 Purine inhibitors of phosphodiesterase (pde) 7 |
| 04/01/2004 | WO2002085897A9 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 04/01/2004 | WO2002076402A3 Fatty amine drug conjugates |
| 04/01/2004 | WO2002070676A9 Use of protein histidine phosphatase |
| 04/01/2004 | WO2002066480A3 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
| 04/01/2004 | WO2002053094A8 Method for detoxifying a carbohydrate containing solution |
| 04/01/2004 | US20040063961 Enzyme inhibitors; antilipemic agents |
| 04/01/2004 | US20040063955 Antichoelsterol agents; cardiovascular disorders; antihistamines; multiple sclerosis; antihistamines |
| 04/01/2004 | US20040063944 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| 04/01/2004 | US20040063942 Spiro-indolines as Y5 receptor antagonists |
| 04/01/2004 | US20040063935 Aliphatic nitrogenous five-membered ring compounds |
| 04/01/2004 | US20040063929 Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same |
| 04/01/2004 | US20040063914 Antibodies against phosphorylated VASP ( vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use |
| 04/01/2004 | US20040063913 Antibodies to human il-1beta |
| 04/01/2004 | US20040063906 Peptide nucleic acid sequences; antibodies for controlling disease; bactericides, viricides |
| 04/01/2004 | US20040063785 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 04/01/2004 | US20040063783 Used to treat pathologies characterized by an oxidative stress condition and a lack of availability of endothelial nitrogen monoxide, such as ischemia, restenosis, erectile dysfunction, hypoxia, transplant rejection and diabetes |
| 04/01/2004 | US20040063781 Compounds active at the glucocorticoid receptor II |
| 04/01/2004 | US20040063780 Pharmaceutical preparations for treatment of type II diabetes and methods for treatment of type II diabetes |
| 04/01/2004 | US20040063775 Five-membered heterocyclic alkanoic acid derivative |
| 04/01/2004 | US20040063773 Adminstering a pyrrole substituted 2-indolinone compound to a human for the treatment of protein kinase related cellular disorders such as cancer, autoimmune disorders, diabetes, rheumatoid arthritis, angiogenesis and osteoarthritis |
| 04/01/2004 | US20040063759 Administering to a mammal, for treatment or prevention of conditions that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, a piperidinone compound |
| 04/01/2004 | US20040063757 Urotensin-ll receptor antagonists |
| 04/01/2004 | US20040063753 N-acetoamino-4-one-Pyridine derivatives are used as Lp-PLA2 (lipoprotein Associated Phospholipase A2) enzyme inhibitor |
| 04/01/2004 | US20040063750 Such as N-propanesulfonyl-((3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl) acetamide which has squalene synthase inhibitory activity |
| 04/01/2004 | US20040063741 Dopamine receptor agonist for treatment of movement disorders/Parkinson's disease |
| 04/01/2004 | US20040063727 Rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, cancer, restenosis; synthesis |
| 04/01/2004 | US20040063720 Tyrosine kinase inhibitors |
| 04/01/2004 | US20040063717 Employing fatty acid oxidation inhibitor; lowering HbA1c, glucose, total cholesterol and/or triglyceride plasma levels; increasing high density lipoprotein concentration; minimizing side effects; ranolazine |
| 04/01/2004 | US20040063716 Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds |
| 04/01/2004 | US20040063707 Azaindole kinase inhibitors |
| 04/01/2004 | US20040063701 Potent and specific serotonin 2 receptor inhibition with low adverse side effects; such as 1-formyl-N-(2-(4-(5H-dibenzo-(a,d)cyclohepten-5-ylidene)-1 -piperidinyl))ethylisonipecot-amide |
| 04/01/2004 | US20040063700 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 04/01/2004 | US20040063693 5-HT2A receptor related disorders; such as 1-(2-(2-fluoro-4-nitrophenoxy)ethyl)-3-(1piperazinyl)-2(1H)-pyrazinone |
| 04/01/2004 | US20040063692 Bazedoxifene treatment regimens |
| 04/01/2004 | US20040063691 Preparation and use of imidazole derivatives for treatment of obesity |
| 04/01/2004 | US20040063690 Cardiovascular disorders; guanylate cyclase activation; diseases associated with disturbed cyclic guanosine monophosphate balance |
| 04/01/2004 | US20040063688 CCR1 receptor antagonists; such as 5-chloro-2-(2-(-3-(4-fluoro-phenoxy)-8-aza-bicyclo(3.2.1)oct-8-yl)-2-oxo -ethoxy)-benzamide |
| 04/01/2004 | US20040063687 Cardiac arrhythmias; potassium channel function inhibitors; such as 7-(3,4-Dichlorophenyl)-6-(5-fluoro-1-methyl-1H-benzimidazol-2-yl)-4,7 -dihydro-5-(methoxymethyl)pyrazolo-(1,5-a)pyrimidine |
| 04/01/2004 | US20040063679 Amidino and guanidino peptidyl compounds; autoimmune diseases |
| 04/01/2004 | US20040063674 Tetracycline compounds having target therapeutic activities |
| 04/01/2004 | US20040063671 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 04/01/2004 | US20040063661 Treatment of statin side effects |
| 04/01/2004 | US20040063647 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 04/01/2004 | US20040063646 Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| 04/01/2004 | US20040063643 Bombesin antagonists |
| 04/01/2004 | US20040063621 Heterocarpine, a human ghrh-binding protein |
| 04/01/2004 | US20040063615 For therapy of diabetes |
| 04/01/2004 | US20040063170 Antidiabetic agents; dietetics; hypoglycemic agents |
| 04/01/2004 | US20040063156 Materials and methods relating to the diagnosis and treatment of diabetes and obesity |
| 04/01/2004 | US20040062847 Oil/fat composition |
| 04/01/2004 | US20040062844 Adduct of amino acid and artificial sweetener |
| 04/01/2004 | US20040061039 Furnace mount and method of installation |
| 04/01/2004 | CA2768674A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| 04/01/2004 | CA2499213A1 Aromatic liver x-receptor modulators |
| 04/01/2004 | CA2497903A1 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient |
| 03/31/2004 | EP1403302A1 Process for producing lactic acid oligomer |
| 03/31/2004 | EP1403270A1 Pde iv inhibitors |
| 03/31/2004 | EP1403256A1 Fused imidazole derivative |
| 03/31/2004 | EP1402886A1 Lipolysis accelerator, cosmetic skin preparation for body weight reduction and food or beverage composition each containing the same, and method for reducing body weight and medicinal use each based on activity of the same |
| 03/31/2004 | EP1402788A1 Body temperature-raising agent of amino acids for eating or drinking and for medical use |
| 03/31/2004 | EP1402786A1 Ximenynic acid |
| 03/31/2004 | EP1402266A2 Determination of risk and treatment of complications of prematurity |
| 03/31/2004 | EP1402264A1 Assay for beta cell toxic macrolides |
| 03/31/2004 | EP1402260A2 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders |
| 03/31/2004 | EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 03/31/2004 | EP1402054A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 03/31/2004 | EP1402021A1 A gene and uses therefor |
| 03/31/2004 | EP1402018A1 Unigene unidirectional antisense library |
| 03/31/2004 | EP1402017A1 Random gene unidirectional antisense library |